About Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
ARMP Key Statistics
| Current Price | $10.60 | Market Cap | $386 million |
|---|---|---|---|
| Daily Change | -3.28% | Volume | 36K |
| 52-Week High | $16.34 | 52-Week Low | $0.90 |
| Sector | Healthcare | Industry | Biotechnology |
ARMP Price Performance
Armata Pharmaceuticals, Inc. stock has returned -3.28% over the past day, -1.49% over the past week, +30.06% over the past month, and +85.96% over the past three months. The stock trades between a 52-week low of $0.90 and a high of $16.34.